Alector Announces Completion Of Enrollment In The Progress-Ad Phase 2 Clinical Trial Of Al101/Gsk4527226 In Individuals With Early Alzheimer’S Disease
April 17 (Reuters) - Alector Inc ALEC.O:
ALECTOR ANNOUNCES COMPLETION OF ENROLLMENT IN THE PROGRESS-AD PHASE 2 CLINICAL TRIAL OF AL101/GSK4527226 IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

Amazon vs. Microsoft: Which Stock Is a Better Buy for 2026 and Beyond?

Tradingkey







